創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 疾患領域別 創薬シーズ一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
20/05/12 GEM183 Direct renin inhibitor (DRI) Blood pressure control and/or prevention of heart failure in patients with chronic hemodialysis i.v. Small molecule Preclinical Injectable formulation of GEM182 (oral formulation in phase-2b), is also being developed for potential use for better blood pressure control and/or prevention of heart failure by chronic intravenous treatment three times per week via vascular access established in patients with chronic hemodialysis. Renin inhbitor may be suitable for such patients who often exhibit hyperreninemia potentially due to residual function of juxtaglomerular apparatus as well as reduced renal blood flow after start of the hemodialysis. Although dialysis patients are mostly unavoidable from hypertension, no optimal treatment has been available yet. GEM183 can fulfill such such rapid growing huge unmet medical needs.
Licensing discussion is available except for China.
問合せ
20/05/12 GEM182 Direct renin inhibitor (DRI) Hypertension (HP), diabetic nephropathy (DKD), chronic hemodialysis, heart failure Oral Small molecule HP : Phase 2 ready, DKD: Phase 3 ready A 2nd generation DRI with better renoprotective effects than ACEi/ARB. Better hypotensive effects than aliskiren is expected due to higher BA, less variability and no food effect following oral treatment. Prolonged renal localization, blood pressure independent renoprotection and positive effect on renal blood flow are evidenced by DRIs. In clinical trials of GEM182 in T2DM patients with microalbuminuria, dose-dependent UACR reduction and increases in remission rate from albuminuria were also seen.
This compound have been developed as mono-therapy (not combined with ACEi/ARB). Therefore, GEM182 has no safety issues seen in aliskiren's ALTITUDE trial due to RAS dual brockade.
Injectable formalution is also developed (ref. GEM183).
Licensing discussion is available except for China.
問合せ
20/05/11 GEM181 Selective HDAC8 inhibitor Solid tumor Oral Small molecule Phase 1 Through several mechanisms exhibited tumor inhibitory activity against many cancers, especially with high HDAC8 protein expression.
Advantages of GEM181
- Able to pass the BBB
- Suppresses angiogensis
- Side effects less than those of curretly marketed drugs
- Simple synthetic method
問合せ
20/05/08 GEM180 Contrasting MRI Contrasting i.v. Nano particle Phase 2 GEM180 is a MRI contrast meium whivch can detect more small liver lesion, compared to marketed product, because of the better contrast. Biopsy confirmed the number of small nodules by GEM180. GEM180 has better imaging results (higher percent signal intensity loss (PSIL) and better consistency) from CT001. So far no obvious severe adverse events seen. Comprehensive patent portofolio exist globally. 問合せ
20/05/08 GEM179 Iron supply Iron deficient anemia i.v. Nano particle Phase 2 GEM179 is a PEGylated Iron oxide nano particle (IOP) with high macropharge uptake efficiency. GEM179 provide higher efficacy and better safety profiles (serum iron, ROS, hypersensitivity, iFGF23). Comprehensive patent portofolio exist globally. 問合せ
20/05/07 GEM178 Anti-VEGF and antibacterial activities Acne, hypertrophic scar, dermatitis Topical skin Small molecule Preclinical - The first topical drug for treating skin redness by inhibiting VEGF.
- Skin redness originates from the neovascularization. Redness of human acne was rapidly removed in a few days with no irritation nor discomfort.
- Strongly inhibited P. acne with an effectiveness >100X clindamycin.
- A 505(b)2 path available.
- US Patent granted.
問合せ
20/05/01 GEM-CVD04 Antiviral, Immunomodulatory, Anticoagulant, Cytokine release control Pre-Exposure and Post Exposure Prophylaxis for COVID-19 Oro- mucosal (dis- solves in the mouth) Small molecules Phase 1* - Multi-targeted action
- Systemic absorption and topical exposure to upper respiratory tract. colonized by COVID-19 virus.
- *Entering Phase 2 for other indication (USA).
- Available for a large clinical trial (GMP).
- Excellent safety profile
- Worldwide patents
問合せ
20/04/27 GEM- CVD03 Fast response oral vaccine COVID-19 Oral Vaccine Phase-1/2 First-in-class COVID-19 immunotherapy to be used as an oral vaccine. This company has a track record to manufacture oral vaccine against highly pathogenic avian flu virus H5N1 on one week time. Oral vaccine will be easier to distribute to a large number of potentially virus-exposed people within very short period of time.
The company is looking for partner who make the company accessing the virus and finance to manufacture the first batch within one week.
問合せ
20/04/27 GEM177 BOTOX Biosimilar Refer to Note Injection Protein Preclinical Equivalent efficacy and similar safety profile (for biosimilar for Allergan Botox)
Manufacturing using plant-derived mediums

Inidication
- Therapeutic applications: strabismus, cerebral palsy, cervical dystonia, neurogenic bladder, migraine, facial spasm, blepharo spasm
- Aesthetic application: all wrinkles produced due to persistent muscular contractions, square jaw reduction, hyperhidrosis
問合せ
20/04/27 GEM176 A new anti-angiogenesis drug Solid tumor* and Retina disorder ** Injection Protein Preclinical Best-in-class product against anti-VEGF agents
The fusion protein of the second domains from VEGF receptor-1 and the Fc portion of human IgG1.
Higher avidity for VEGF/PLGF and low immunogenicity and side effect.
*More complete blockade of Tumor growth. (pancreatic cancer, liver cancer, gastric cancer, non-small cell lung cancer)
**Longer duration of action (wet AMD, Diabetic macular edema, retinal vein occlusion, diabetic retinopathy)
問合せ